The effectiveness of botulinum toxin type A (BTX‐A) in the treatment of facial skin oily seborrhea, enlarged pores, and symptom complex of post‐acne. (3rd May 2021)

• Record Type: Journal Article
• Authors: Shirshakova, Maria; Morozova, Elena; Sokolova, Daria; Pervykh, Svetlana; Smirnova, Lyudmila
• Is Part Of: International journal of dermatology. Volume 60:Number 10(2021)
• Page Start: 1232
• Page End: 1241
• Publication Date: 2021-05-03
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/ijd.15574
• Languages: English
• ISSNs: 0011-9059

Abstract

Abstract: Background: This study aimed to examine the effectiveness of botulinum toxin type A (BTX‐A) in the treatment of acne. Methods: The study was conducted in 2018 on 12 patients, 10 females and two males, aged 35 years on average. The injections with BTX‐A were given during 2 weeks into the face skin in a dosage of 0.125–0.250 units. Results: Skin moisture indexes increased during the therapy by 4% ( P ≤ 0.05), and porosity decreased by 7% ( P ≤ 0.01). Maximal changes were recorded for the sulci and pigmentation of the skin, namely, its values decreased by 10 and 9%, respectively ( P ≤ 0.01). BTX‐A is recommended for an application not only in plastic surgeries but also for local correction of acne on the patient's skin. Conclusion: A positive correlation was revealed between the duration of treatment and reduction of skin oiliness (0.87), pigmentation (0.78), skin sulci (0.84), and skin porosity (0.88), and negative correlation was established with increased skin moisture (−0.64). The obtained dependencies apply for the therapy period of up to 2 weeks. Pharmacological properties of BTX‐A allow recommending it as a drug used in post‐acne therapy.